Transforming health with cell therapies focused on tissue and bone repair.
A new Allogeneic Cell Therapy Frontier
Potential
The potential of off-the-shelf cell therapies is transforming the healthcare landscape.
Sapphiros AI Bio is leading the way in leveraging established and emerging technologies to develop treatments for tissue repair.
Regenerative Medicine
We are using our proprietary cell bank of over 85,000 donor lines to develop new treatments and medical breakthroughs. By harnessing the power of pluripotent stem cells and cells differentiated from them, our cell lines are used to bridge the gap between research and development and potential therapies.
The vast array of donor sample lines in our cell bank, and the qualities that they exhibit or have been correlated with, allow us to explore a wide range of genetic variations and characteristics impacting disease, conditions and other indications, providing an exceptional platform for studying and understanding the intricacies of the human body. From these learnings, new cell-based therapies may be developed.
Initial Therapeutic Program
Our first therapeutic program, currently in preclinical development, is focused on a customized combination of cell types tailored to maximize the regeneration of damaged cartilage tissue.
We have completed two preclinical animal studies with promising results using our proprietary, human derived cellular product.
We also have significant R&D and intellectual property in cardiac and other therapeutic targets for future development.
